login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
IMMIX BIOPHARMA INC (IMMX) Stock News
USA
- NASDAQ:IMMX -
US45258H1068
-
Common Stock
2.5
USD
-0.08 (-3.1%)
Last: 10/10/2025, 9:35:44 PM
2.52
USD
+0.02 (+0.8%)
After Hours:
10/10/2025, 9:35:44 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IMMX Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: Immix Biopharma, Inc.
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
6 days ago - By: Immix Biopharma, Inc.
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
12 days ago - By: Immix Biopharma, Inc.
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
12 days ago - By: Immix Biopharma, Inc.
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
24 days ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
24 days ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
a month ago - By: Immix Biopharma, Inc.
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
a month ago - By: Immix Biopharma, Inc.
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
a month ago - By: Benzinga
- Mentions:
BRKR
CLDX
KPTI
MBOT
...
12 Health Care Stocks Moving In Monday's After-Market Session
a month ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
a month ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
2 months ago - By: Immix Biopharma, Inc.
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
2 months ago - By: Immix Biopharma, Inc.
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
2 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Other Serious Diseases Strategy
2 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Other Serious Diseases Strategy
3 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
3 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
3 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
3 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
4 months ago - By: Zacks Investment Research
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
4 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Attends FDA CEO Forum in Washington DC
4 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Attends FDA CEO Forum in Washington DC
4 months ago - By: Yahoo Finance
- Mentions:
RMBS
ONC
SERV
UBER
...
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
4 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
4 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
5 months ago - By: Benzinga
- Mentions:
EVO
RAPT
ONCO
ALTS
...
12 Health Care Stocks Moving In Friday's Intraday Session
5 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
5 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
5 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
5 months ago - By: Immix Biopharma, Inc.
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
5 months ago - By: Immix Biopharma, Inc.
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
5 months ago - By: Immix Biopharma, Inc.
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
Please enable JavaScript to continue using this application.